Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Cidara Therapeutics (NASDAQ:CDTX) and maintained a $25 price target.
August 14, 2024 | 9:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Cidara Therapeutics and maintained a $25 price target.
The reiteration of a Buy rating and the maintenance of a $25 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100